Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $158.08, for a total transaction of $110,656.00. Following the completion of the sale, the chief financial officer now directly owns 32,768 shares of the company’s stock, valued at approximately $5,179,965.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Jazz Pharmaceuticals stock traded up $3.38 during mid-day trading on Friday, reaching $145.57. The stock had a trading volume of 1,051,546 shares, compared to its average volume of 631,079. Jazz Pharmaceuticals PLC has a one year low of $130.15 and a one year high of $184.00. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.29 and a quick ratio of 3.62. The stock has a market cap of $8.47 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.76 and a beta of 1.06.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.32 by $0.26. The firm had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.22 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 11.71 EPS for the current fiscal year.
JAZZ has been the subject of several recent research reports. Evercore ISI restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Friday, July 13th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 16th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $203.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $191.94.
Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its holdings in Jazz Pharmaceuticals by 113.7% in the second quarter. Russell Investments Group Ltd. now owns 68,430 shares of the specialty pharmaceutical company’s stock worth $11,798,000 after acquiring an additional 36,415 shares in the last quarter. Legal & General Group Plc raised its position in Jazz Pharmaceuticals by 1.8% during the second quarter. Legal & General Group Plc now owns 241,295 shares of the specialty pharmaceutical company’s stock valued at $41,575,000 after acquiring an additional 4,268 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Jazz Pharmaceuticals by 19.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 260,768 shares of the specialty pharmaceutical company’s stock valued at $44,931,000 after acquiring an additional 42,463 shares in the last quarter. LPL Financial LLC raised its position in Jazz Pharmaceuticals by 27.7% during the first quarter. LPL Financial LLC now owns 4,801 shares of the specialty pharmaceutical company’s stock valued at $725,000 after acquiring an additional 1,041 shares in the last quarter. Finally, Castleark Management LLC increased its position in shares of Jazz Pharmaceuticals by 31.9% in the second quarter. Castleark Management LLC now owns 43,795 shares of the specialty pharmaceutical company’s stock valued at $7,546,000 after buying an additional 10,595 shares in the last quarter. 92.95% of the stock is currently owned by institutional investors.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.